Literature DB >> 8895554

c-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model.

R M Pascale1, M R De Miglio, M R Muroni, M M Simile, L Daino, M A Seddaiu, A Nufris, L Gaspa, L Deiana, F Feo.   

Abstract

We have investigated by restriction fragment analysis genomic abnormalities involving the c-myc gene in DNA isolated from adenomas and hepatocellular carcinomas (HCCs). Adenomas and HCCs were induced by the "resistant hepatocyte" protocol in diethylnitrosamine-initiated male F344 rats. Southern-blot analysis of EcoRI-restricted DNA from normal liver, early and late adenomas, 12 weeks (EAs) and 30 weeks (LAs) after initiation, and HCCs, showed 2 bands of 18 and 3.2 kb hybridizing with c-myc, in all tissues. c-myc amplification occurred in almost all HCCs, and in the majority of EAs and LAs. These results were confirmed by dilution analysis. c-myc amplification was also seen in adenomas and HCCs by Southern analysis with HindIII-restricted DNA, and in HCCs by differential PCR. c-myc mRNA increase occurred in all adenomas and HCCs, but it was higher in the lesions showing gene amplification. Moreover, a 13-kb DNA extraband, hybridizing with c-myc, was found in the HindIII-restricted DNA from HCCs, but not in normal liver and adenomas, and a 7.1-kb extra band was present in EcoRI-digested DNA from one LA. EcoRI-restricted DNA from some adenomas exhibited a decrease in intensity of the 18-kb fragment, and an increase in intensity of the 3.2-kb fragment. No alteration in banding pattern occurred in the beta-actin gene in adenomas. These results provide evidence of amplification and some other rearrangements involving the c-myc gene, in pre-malignant and malignant liver lesions, induced by the RH protocol, and suggest a role of c-myc rearrangement in the progression of adenomas to malignancy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895554     DOI: 10.1002/(SICI)1097-0215(19960927)68:1<136::AID-IJC24>3.0.CO;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Determination of copy number of rRNA genes in Pneumocystis carinii f. sp. hominis.

Authors:  X Tang; M S Bartlett; J W Smith; J J Lu; C H Lee
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 2.  MYC Deregulation in Primary Human Cancers.

Authors:  Manpreet Kalkat; Jason De Melo; Katherine Ashley Hickman; Corey Lourenco; Cornelia Redel; Diana Resetca; Aaliya Tamachi; William B Tu; Linda Z Penn
Journal:  Genes (Basel)       Date:  2017-05-25       Impact factor: 4.096

3.  Beta-catenin (Ctnnb1) gene mutations in diethylnitrosamine (DEN)-induced liver tumors in male F344 rats.

Authors:  Y Yamada; N Yoshimi; S Sugie; M Suzui; K Matsunaga; K Kawabata; A Hara; H Mori
Journal:  Jpn J Cancer Res       Date:  1999-08

4.  LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.

Authors:  Ji Liu; Rui Xu; Shi-Juan Mai; Yu-Shui Ma; Mei-Yin Zhang; Ping-Sheng Cao; Nuo-Qing Weng; Rui-Qi Wang; Di Cao; Wei Wei; Rong-Ping Guo; Yao-Jun Zhang; Li Xu; Min-Shan Chen; Hui-Zhong Zhang; Long Huang; Da Fu; Hui-Yun Wang
Journal:  Theranostics       Date:  2020-06-12       Impact factor: 11.556

Review 5.  Experimental Models to Define the Genetic Predisposition to Liver Cancer.

Authors:  Rosa M Pascale; Maria M Simile; Graziella Peitta; Maria A Seddaiu; Francesco Feo; Diego F Calvisi
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.